Provided by Tiger Trade Technology Pte. Ltd.

Avalo Therapeutics Inc

18.22
-0.6350-3.37%
Volume:388.99K
Turnover:7.27M
Market Cap:337.21M
PE:-2.08
High:19.08
Open:18.92
Low:17.75
Close:18.85
52wk High:20.72
52wk Low:3.39
Shares:18.51M
Float Shares:11.60M
Volume Ratio:2.00
T/O Rate:3.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7421
EPS(LYR):-20.9087
ROE:-174.79%
ROA:-37.18%
PB:3.68
PE(LYR):-0.87

Loading ...

Avalo Therapeutics Inc expected to post a loss of $1.66 a share - Earnings Preview

Reuters
·
Nov 03, 2025

Avalo Therapeutics to Participate in Piper Sandler Annual Healthcare Conference

Reuters
·
Nov 03, 2025

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Anavex Life Sciences (AVXL)

TIPRANKS
·
Oct 29, 2025

BRIEF-Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa

Reuters
·
Oct 29, 2025

Avalo Therapeutics - Lotus Trial Enrolls 250 Patients, Topline Data From Trial Is Expected in Mid-2026.

THOMSON REUTERS
·
Oct 29, 2025

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa

THOMSON REUTERS
·
Oct 29, 2025

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX)

TIPRANKS
·
Oct 17, 2025

Avalo Therapeutics Inc publishes presentation on advancing IL1β therapies for hidradenitis suppurativa

Reuters
·
Oct 10, 2025

Avalo Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Boyd Taylor

Reuters
·
Oct 07, 2025

Avalo Therapeutics Files Initial Beneficial Ownership Statement for Director Kevin Robert Lind

Reuters
·
Oct 03, 2025

Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources

TIPRANKS
·
Oct 01, 2025

Avalo Therapeutics Announces New Inducement Compensation Plan Amid Leadership Expansion

Reuters
·
Oct 01, 2025

Press Release: Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Dow Jones
·
Oct 01, 2025

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

TIPRANKS
·
Sep 29, 2025

Avalo Therapeutics appoints Kevin Lind to board of directors

TIPRANKS
·
Sep 22, 2025

Press Release: Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Dow Jones
·
Sep 22, 2025

Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains

Simply Wall St.
·
Sep 16, 2025

Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data

TIPRANKS
·
Sep 16, 2025

Avalo Therapeutics (AVTX) Gets a Buy from Oppenheimer

TIPRANKS
·
Sep 15, 2025

Avalo Therapeutics (AVTX) Receives a Buy from Piper Sandler

TIPRANKS
·
Sep 11, 2025